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CLiNICAL REPORT 
A 24-yr-old woman was investigated for acrocyanosis and 
ehest, axillary and abdominallymph nodes. An anaplastie large 
B eell non-Hodgkin's Iymphoma was diagnosed by biopsy of a 
left axillary node and was treated by 4 courses of ACVBP ehem-
otherapy (adriamycin, eydophosphamide, vindesin, bleomy-
cine, methylprednisolone and intratheeal methotrexate) with a 
total amount of 80 mg of bleomycin over eight weeks. A com-
plete tumour response was achieved. Two months later, she 
developed dyspnea and a non-respiratory dependent left 
chest pain limiting progressively her physical aetivities. Fune-
tional respiratory assessment showed a restrictive pattern 
(foreed vital eapacity (FVC) 1.79 L, (46% of the predieted value 
(PV)), diffusion capacity of the lung for carbon monoxide at 32% 
of the predieted value, total lung eapacity (TLC) 326 L (61 % 
PV). Chest computed tomography (CT) showed a pneumome-
diastinum and parietal emphysema with multifoeal interstitial 
infiltrations predominant in the left lower lobe (Figure 1). Bron-
choalveolar lavage was not contributive (140 white blood cells 
per mm' with 6% of neutrophils, 3% of lymphocytes and 86% 
of macrophages). Lung surgieal biopsy refuted infeetious or 
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Figure 1: Chest computed tomography (U) showing a pneumomedi-
astinum and parietal emphysema with multifocal interstitial 
infiltrations predominant in the left fower lobe. 
neoplasic aetiologies but confirmed an interstitial pneumonia 
due to bleomycin (Figure 2). Bleomycin was stopped and sys-
temie cortieotherapy begun. Seven months later, FVC and TLC 
hadimproved (2.50 liters, 64% PV and 3.93 liters, 74% PV, 
respeetively) with dinieal and radiologieal recovery (Figure 3). 
DISCUSSION 
Bleomycin is an antibiotic drug with antitumoural activ-
ity used for the treatment of germ eell tumours and Hodgkin's 
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Figure 2: Lung surgical biopsy confirme an interstitial pneumonia. 
Figure 3: Radiological recovery with improved chest computed tomo~ 
graphy images when bleomycin ;5stopped. 
bleomycin hydrolase, but this enzyme is not found in the lung 
and the skin which might expia in the high toxicity of the drug 
on these organs. Bleomycin can induce cell damage through 
lipid peroxidation.ln the lung it can cause alveolar cell destruc-
tion leading to pulmonary infiammation. Pulmonary toxicity of 
bleomycine is the mast feared side-effect of this medication. 
Several pulmonary diseases have been associated with the use 
of bleomycin, such as cryptogenic organising pneumonia, 
eosinophilic hypersensitivity and interstitial pneumonitis(l) . 
Ngeow et al published a prospective study of 184 patients 
treated for Hodgkin's Iymphoma by adriamycin, bleomycin, vin-
blastine and dacarbazine (2). Bleomycin-induced pneumonitis 
(BIP) developed in 15% of the patients.The mortality rate of BIP 
is close to 3%. Pulmonary toxicity of bleomycin is a dose-
dependent effect, and has been described at cumulative dose 
higher than 100 mg. Only two cases of pneumomediastinum 
have been described with BIP and in these cases, the patients 
received high dose of bleomycin (225 mg and 300 mg, respec-
tively) (3). We postulate that oxidative alveolar damages caused 
by bleomycin lead to pneumomediastinum by air leakage in the 
mediastinum. 
Patients older than 70 years have a higher risk to develop 
BIP. Bleomycin is excreted by the kidney. Sleijfer et al showed 
that the incidence of BIP is correlated with the decrease of 
renal function (4). Lei et al have demonstrated that Granulocyte 
Colony-Simulating Factor (G-CSF) used during bleomycin 
based chemotherapy enhanced the risk of respiratory failure. 
Bleomycin lung toxicity is partially due to the production of 
oxidants and G-CSF exacerbates this phenomenon by increas-
ing superoxide release by neutrophils in response to stimuli (5). 
Administration of high inspired oxygen fraction (ould exacer-
bate the production of oxidants and so increase the risk of BIP. 
ln a review of 10 patients suffering from BIP White et al. 
found that dyspnea, dry cough, tachypnea and cyanosis were 
the presenting symptoms in nine patients; one was asympto-
matie (6). Radiographie presentation of BIP is a bibasal reticular 
or fine nodular infiltrates. Findings are sim ilar but are detected 
earlier on CT scan and impose to exclude other diagnoses su ch 
as metastasis or infectious pneumonitis. Decreasing FVC is 
more in relationship with bleomycin toxicity than TLCO (3). 
ln the serie of ten patients described above, White et al. 
showed the efficacy of corticosteroids for the treatment of BIP 
(6). Seven patients were treated by corticosteroids and ini-
tially improved. After lowering the dose, 5 patients had a 
relapse of BIP. By contra st the 3 untreated patients died 
quickly. To the best of our knowledge there is no other pub-
lished study that supports the efficacy of corticosteroids in 
BIP. But in patients with BIP, the most important is to avoid 
further bleomycin administration. Extensive architectural dis-
torsion seen in BI? can lead to a pneumomediastinum. 
CONCLUSION 
Our case highlights the occurrence of BIP after low-dose 
bleomycin. The absence of a risk factor must remind us that BIP 
can occur during bleomycin treatment in any patient and that 
we should follow FVC during such therapy. Furthermore, this is 
the first case in wich a pneumomediastinum without associ-
ated pneumothorax was reported with low dose of bleomycin. 
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